Update on the provisional estimation of developing iatrogenic variant Creutzfeldt-Jakob disease from human islet cell transplantation procedures

Transplantation

Volumn 97, Issue 12, 2014, Pages

  Tyshenko, Michael G ^a   Bertram, Lisa ^b,c   Li, Li ^b,c   Elsaadany, Susie ^d   Samis, John ^e   Krewski, Daniel ^a   Cashman, Neil R ^b,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c PrioNet Canada   (Canada)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^e UNIVERSITY OF ONTARIO INSTITUTE OF TECHNOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; LIBERASE; PRION PROTEIN;

BRAIN HOMOGENATE; CELL ISOLATION; DISEASE TRANSMISSION; DISSOCIATED CELL CULTURE; HIGH RISK PATIENT; HUMAN; IATROGENIC CREUTZFELDT JAKOB DISEASE; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; LETTER; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; QUALITY CONTROL; QUANTITATIVE STUDY; TREATMENT DURATION;

ANIMALS; BRAIN; COLLAGENASES; CREUTZFELDT-JAKOB SYNDROME; DIABETES MELLITUS, TYPE 1; HUMANS; IATROGENIC DISEASE; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICE, TRANSGENIC; PRIONS; RISK ASSESSMENT; RISK FACTORS; THERMOLYSIN; TISSUE AND ORGAN HARVESTING;

EID: 84902459336     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000176     Document Type: Letter

References (13)

1. Shapiro AM, Ricordi C, Hering BJ, et al. Modeling rare and emerging diseases for decision making and policy implementation: extreme values and data management. Bioprocess Int 2004; 2: 30.
2. Paget M,Murray H, Bailey CJ, et al. Human islet isolation: semi-automated and manual methods. Diab Vasc Dis Res 2007; 4: 7.
3. Heim D, Kihm U. Risk management of transmissible spongiform encephalopathies in Europe. Rev Sci Tech 2003; 22: 179.
4. ElSaadany S, Tyshenko MG, Oraby T, et al. The risk to human islet cell transplant recipients of acquiring variant Creutzfeldt-Jakob disease: a provisional quantitative risk assessment. Transplantation 2011; 92: e2.
5. Will RG. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br Med Bull 2003; 66: 255.
6. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363: 417.
7. Amselgruber WM, Büttner M, Schlegel T, et al. The normal cellular prion protein (PrPc) is strongly expressed in bovine endocrine pancreas. Histochem Cell Biol 2006; 125: 441.
8. Strom A, Wang GS, Reimer R, et al. Pronounced cytosolic aggregation of cellular prion protein in pancreatic beta-cells in response to hyperglycemia. Lab Invest 2007; 87: 139.
9. Guest WC, Plotkin SS, Cashman NR. Toward a mechanism of prion misfolding and structural models of PrP(Sc): current knowledge and future directions. J Toxicol Environ Health A 2011; 74: 154.
10. Public Health Agency of Canada. 2008. Preliminary quantitative risk assessment of developing variant Creutzfeldt-Jakob disease (vCJD) from human islet cell transplantation. Available at: http://www.med.uottawa. ca/sites/tsalem/documents/Islet%20Risk% 20Assessment%20-%20Feb%2018,2008% 20-%20final.pdf. Accessed May 22, 2013.
11. Roche Applied Science. 2013. Liberase R1 for rodent islet isolation, for dissociation of 40 rodent pancreata. December 2006. Available at: https://cssportal.roche.com/LFR-PublicDocs/ras/11815032001-en-04.pdf. Accessed May 4, 2013.
12. Roche Applied Science. 2013. Protocol for Rodent Pancreas Dissociation. Available at: http://www.roche-applied-science.com/webapp/wcs/stores/servlet/ PrintView?langId=-1&storeId=15016&articleId=68036. Accessed May 4, 2013.
13. Roche Applied Science. 2013. Liberase Research Grade Insights-Liberase Enzyme Technology. Available at: http://www.roche-appliedscience. com/webapp/wcs/stores/servlet/PrintView? langId=-1&storeId= 15016&articleId=68036. Accessed May 4, 2013.